Kiniksa Pharmaceuticals, Ltd. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Unaudited consolidated financial statements; comparison is with Q1 2020. Amounts below are in U.S. dollars unless noted.
Business context
Kiniksa is a biopharmaceutical company developing immunology medicines and began commercializing ARCALYST (rilonacept) in the United States after FDA approval for recurrent pericarditis on March 18, 2021. It assumed U.S. sales and distribution for ARCALYST’s approved indications and shares profits with Regeneron after specified commercialization expenses, subject to limits. Its other highlighted programs are mavrilimumab, vixarelimab and KPL-404.
Financial performance and position
| Metric | Q1 2021 / March 31, 2021 | Q1 2020 / December 31, 2020 |
|---|---|---|
| Product revenue | No product revenue reported for the quarter | No product revenue reported |
| Research and development expense | $28.7 million | $20.9 million |
| Selling, general and administrative expense | $20.6 million | $8.5 million |
| Total operating expenses / operating loss | $49.3 million | $29.4 million |
| Net loss | $49.5 million; $0.72 per share | $26.4 million; $0.48 per share |
| Cash used in operating activities | $40.1 million | $31.8 million |
| Cash, cash equivalents and short-term investments | $264.0 million | $323.5 million |
| Total assets / total liabilities | $311.2 million / $40.5 million | $349.5 million / $37.5 million |
Revenue-based margins are not meaningful because the filing reports no product revenue in the quarter. No borrowings or other funded debt are reported on the balance sheet; liabilities include operating leases. Current assets were $275.6 million and current liabilities $35.5 million. Management said available cash, cash equivalents and short-term investments were expected to fund operations and capital expenditure requirements for at least 12 months from issuance of the financial statements.
Material changes versus Q1 2020
- Net loss increased $23.1 million, while total operating expenses rose $19.9 million. R&D increased $7.8 million, primarily from the mavrilimumab Phase 2/3 COVID-19 trial and higher unallocated personnel costs; ARCALYST and KPL-404 program costs declined.
- SG&A increased $12.1 million, mainly from $7.8 million higher personnel-related costs and $3.2 million of ARCALYST pre-commercialization expenses.
- Operating cash use rose $8.3 million. Interest income fell to $9,000 from $789,000, which the company attributed primarily to lower interest rates.
- Cash, cash equivalents and short-term investments declined $59.5 million from year-end 2020. Cash and cash equivalents alone increased to $119.9 million from $114.0 million, while short-term investments decreased to $144.2 million from $209.4 million.
Outlook, commentary and risks
- The filing provides no quantified revenue or earnings guidance. Management expects significant operating losses and substantial R&D and commercialization spending for the foreseeable future; profitability is uncertain.
- In March, Kiniksa paid Regeneron a $20.0 million regulatory milestone, recorded as a finite-lived intangible asset to be amortized over 20 years. It also reported $17.1 million of non-cancelable manufacturing commitments, all due within one year.
- Commercial execution risks include limited company experience in marketing and distribution, payor coverage and reimbursement, market adoption, and dependence on Regeneron as ARCALYST’s sole-source manufacturer. The company reported a specialty cardiology sales force of approximately 30 representatives.
- Development risks include clinical uncertainty, competition for patients, manufacturing and supply constraints, and possible delays or disruption from COVID-19. The filing also highlights capital-raising needs beyond the stated 12-month liquidity horizon and potential dilution or restrictive financing terms.
- Program milestones described include an ongoing vixarelimab Phase 2b trial in prurigo nodularis and a planned KPL-404 Phase 2 trial in rheumatoid arthritis in the second half of 2021. The company expected to provide next steps for mavrilimumab development, including GCA, in Q2 2021. These are forward-looking statements, not guarantees.
- Post-quarter updates included April 2021 Phase 2 data for mavrilimumab in severe COVID-19 pneumonia and May 2021 KPL-404 Phase 1 data; these events occurred after the reporting period. The filing says the KPL-404 Phase 2 trial was planned for the second half of 2021.
- No material legal proceedings were reported. Management judged disclosure controls effective as of March 31, 2021; the company completed migration of its legacy accounting system to SAP during the quarter.
Investor verification priorities
- Confirm whether ARCALYST generated sales after launch, the pace of prescriptions and access, and the net economics of the profit-sharing arrangement with Regeneron.
- Track actual cash burn against management’s at-least-12-month liquidity estimate, including commercialization costs, the $17.1 million manufacturing commitments and future financing needs.
- Review complete clinical results and subsequent regulatory or trial updates for mavrilimumab, vixarelimab and KPL-404; distinguish interim or topline data from final results.
- Assess ARCALYST supply continuity and manufacturing concentration, along with payor coverage, reimbursement and competitive developments.
- Check share dilution and voting-control implications of the multi-class share structure and outstanding options and restricted share units.